Human TFPI-2 Protein
- Known as:
- Human TFPI-2 Protein
- Catalog number:
- TF2-H5227
- Product Quantity:
- 1mg
- Category:
- -
- Supplier:
- acrobyosystems
- Gene target:
- Human TFPI-2 Protein
Related genes to: Human TFPI-2 Protein
- Gene:
- TFPI2 NIH gene
- Name:
- tissue factor pathway inhibitor 2
- Previous symbol:
- -
- Synonyms:
- PP5, TFPI-2, REF1
- Chromosome:
- 7q21.3
- Locus Type:
- gene with protein product
- Date approved:
- 1999-07-14
- Date modifiied:
- 2016-10-05
Related products to: Human TFPI-2 Protein
Related articles to: Human TFPI-2 Protein
- Breast cancer (BC) incidence continues to rise, and recurrence and metastasis remain major contributors to mortality. The epithelial-mesenchymal transition (EMT), associated with the acquisition of invasive functions by epithelial cells, also promotes resistance to anticancer therapies. Here, an EMT-based prognostic model was developed to enhance BC outcome prediction. - Source: PubMed
Publication date: 2026/03/15
Wu ZizhengZheng JieMen ShuaiSui ShuangruiYan WeitaoLiu YinfengHan Meng - Trophoblast dysfunction and abnormal cell death are associated with unexplained spontaneous miscarriage (USM), while the underlying mechanisms remain unclear. This research aims to elucidate the pathogenic functions of the RNA-binding protein KH-type splicing regulatory protein (KHSRP) in USM. - Source: PubMed
Publication date: 2026/03/31
Jin GehuiHuang JinyuanWang XiaoyeFan MengjieWu WenxueSun YueLiu XueTian Chan - Glioblastoma (GBM) is a highly aggressive brain tumor characterized by extensive crosstalk between glioblastoma stem cells (GSCs) and immunosuppressive microglia, with our previous work identifying CLOCK and TFPI2 as key regulators of this interaction. Here, we uncover a 'symbiotic exclusivity' pattern between CLOCK and TFPI2, showing that despite mutually exclusive amplifications, they sustain symbiotic regulatory interactions in GBM. The CLOCK-BMAL1 complex transcriptionally upregulates TFPI2, while TFPI2-driven hypoxia inducible factor 1 alpha (HIF1a) signaling activates nuclear factor kappa B (NF-kB) P65 to upregulate the CLOCK-BMAL1 complex, creating a positive feedback loop to promote stemness, immunosuppression, and tumor progression. Disrupting the CLOCK-TFPI2 interplay through dual inhibition of their downstream effectors reduces GSC stemness and immunosuppressive microglia, activates antitumor immunity, and synergizes with anti-PD1 therapy to achieve complete tumor regression in 50-62.5% of tumor-bearing mice. This study uncovers a promising therapeutic strategy for a broader subset of GBM patients with high expression of either CLOCK or TFPI2, and provides a framework for identifying 'symbiotic exclusivity' genes in cancer. - Source: PubMed
Publication date: 2026/03/17
Zhou FeiPang LizhiLiu YangKhan FatimaChen Peiwen - Breast cancer (BRCA) is a common malignant tumor in women globally and has a poor prognosis. Molecular targeted therapy is a promising way for improving the treatment of BRCA. This study aimed to identify potential biomarkers for BRCA and construct a prognostic model. - Source: PubMed
Publication date: 2026/02/12
Xia ManzhiDong ShufengCao JieWang JiaWang Chunlei - Colorectal neoplasia is a significant global health burden. Early detection is critical for improving clinical outcomes. However, developing a noninvasive strategy for routine detection of colorectal neoplasia remains challenging. This study evaluated the diagnostic performance of a combined SDC2/SFRP2/TFPI2 gene methylation stool DNA test for detecting colorectal cancer (CRC) and advanced adenoma (AA). - Source: PubMed
Publication date: 2026/01/30
Li XiaopingLiao QiuyuYang WenhuiXiong ZhiguoHolmes MarkLi KaiyuPan JieYan JingLiu Gang